Description

GenieBiome, a biotechnology spinout from The Chinese University of Hong Kong was founded by world-renowned clinician-scientists and supported by a multidisciplinary team of experts in microbiology, metagenomics, bioinformatics, disease biomarkers, food technology, clinical trials, IP development and commercialization. For over a decade, our team has pioneered the use of microbiome with evidence-based science to tackle a myriad of diseases, including novel virus, gut serious illness, overweight and metabolic syndrome, skin irritation and mental health.

Our precision portfolio of G-NiiB includes diagnostic and risk prediction tests, next-generation microbiome precision formula, and precision medicine tailored for the Asian population.

We use our unique metagenomics database to identify novel microbes as diagnostic tools and generate personalised therapy for conditions with unmet needs (Microbiome Precision). We offer tailored-made microbial replacement therapy to restore imbalance in gut microbes to improve health outcomes and prevent diseases.

We pursue infinite innovations that is beyond our imaginations, and to achieve the mission impossible. G-NiiB is building the world’s largest Microbiome Asian Big data to fulfil our mission to provide evidence based targeted solutions for the healthy future of the Next Generations.